Archived AES Symposia 2005
Program Length: 1 hrs 20 min
OverviewThe major goal of this symposium is to review several exciting and controversial topics relating to the pathophysiology, diagnosis and treatment of epilepsy. While there is no single theme for this symposium, the five presentations will cover diverse topics from the epilepsy spectrum including the integration of functional brain assessment techniques (MEG, MRI-DTI and EEG) to identify the epileptogenic zone, an updated understanding of mechanisms of anti-epileptic drug resistance, recent variations on the classic ketogenic diet theme, insights into subcortical epileptogenesis emerging from the study of the hypothalamic hamartoma, and a re-examination of the concept of the epileptic focus (a single focus, or rather multiple foci within a complex multi-nodal network). The presentations will all be translational in scope, highlighting important clinical questions that can be better understood from diverse technological and laboratory perspectives.
At the conclusion of this activity, participants should be able to:
- Outline the usefulness of applying MEG, MRI and EEG techniques toward the identification of a surgically-remediable epileptic focus/zone
- Analyze why certain antiepileptic drugs fail to completely control seizures in patients
- Determine how modifications to the classic ketogenic diet might improve tolerability without sacrificing efficacy for patients for whom this diet is appropriate
- Assess the study of a rare disorder (i.e., the hypothalamic hamartoma) summarizing the insights into the mechanisms of subcortical epileptogenesis
- Given that seizures likely represent a network phenomenon with multiple interdependent nodes, reinterpret the concept of the epileptic focus.
Clinicians and professionals in epilepsy care, basic science and clinical researchers, pharmacists as well as trainees in the field of epilepsy.
Chair: Jong M. Rho, M.D.
Many Lesions, One Focus: Integration of MEG, MRI-DTI and EEG
Joyce Wu, M.D.
Disclosure: It is the policy of the American Epilepsy Society that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. The American Epilepsy Society adheres to the ACCMEs Essential Areas and Policies regarding industry support of continuing medical education. Disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
Jaideep Kapur, M.D., Ph.D. has indicated he has no real or apparent conflicts of interest to report.
John F. Kerrigan, M.D. has indicated he has no real or apparent conflicts of interest to report.
Dean K. Naritoku, M.D. has indicated he has received consulting fees from Abbott Laboratories, Ortho McNeil Neurologics, Inc. and Eisai, Inc. Dr. Naritoku has also indicated he has received fees for non-CME services from Abbott Laboratories, Ortho McNeil Neurologics, Inc., Eisai Inc. and Glaxo Smith Kline and has contracted research for Abbott Laboratories, Ortho McNeil Neurologics, Inc. Glaxo Smith Kline, IVAX and Schwarz Pharma.
Jong M. Rho, M.D. has indicated he has received consulting fees and fees for non-CME services from Eisai, Inc., Ortho McNeil Neurologics, Inc., UCB Pharma and Valeant Pharmaceuticals and has contracted research for Eisai, Inc.
Elizabeth Thiele, M.D., Ph.D. has indicated she has received fees for non-CME services from UCB Pharma, GlaxoSmithKline, Ortho McNeil Neurologics, Inc., Cyberonics and Pfizer Inc.
L. James Willmore, M.D. (liaison reviewer) has disclosed that he has ownership interest in Pfizer Inc.
Joyce Wu, M.D. has indicated she has no real or apparent conflicts of interest to report.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.